Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease

  • L. Meloni
  • M. R. Manca
  • I. Loddo
  • G. Cioglia
  • P. Cocco
  • A. Schwartz
  • S. Muntoni
  • Sa. Muntoni
Original Article


Previous studies suggest a reduction in cardiovascular risk among subjects expressing the glucose-6-phosphate dehydrogenase (G6PD, EC deficient phenotype. We aimed to test this hypothesis in male subjects expressing the G6PD-deficient phenotype vs wild type G6PD. In a case–control study we examined consecutive patients admitted for acute myocardial infarction or unstable angina, and controls admitted for diagnoses other than coronary heart disease (CHD). The G6PD phenotype was determined by measuring the enzyme activity in erythrocytes, as the absorbance rate change due to NADPH reduction. The CHD risk associated with the G6PD phenotype was assessed with unconditional logistic regression. G6PD-deficient subjects were less frequently represented among cases (11.8%) than among controls (18.6%, p=0.002). The genetic condition of G6PD deficiency conveyed a significant reduction in CHD risk (OR=0.6; 95% CI 0.4 to 0.9). We confirm the hypothesis that subjects with the G6PD-deficient phenotype are less prone to CHD. We suggest that such a protective effect may be ascribable to a reduced 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA R) activity, a statin-like effect, as well as to a downregulation in NADPH oxidase activity with a consequent reduction in oxygen-free radical production.


NADPH Oxidase Coronary Heart Disease Risk G6PD Deficiency Fava Bean Coronary Heart Disease Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Babior BM (1999) NADPH oxidase: an update. Blood 93: 1464–1476.PubMedGoogle Scholar
  2. Battistuzzi G, D’Urso M, Toniolo D, Persico GM, Luzzatto L (1985) Tissue-specific levels of human glucose 6-phosphate dehydrogenase correlate with methylation of specific sites at the 3′ end of the gene. Proc Natl Acad Sci USA 82: 465–469.CrossRefGoogle Scholar
  3. Beutler E (1991) Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 324: 169–174.PubMedGoogle Scholar
  4. Bilmen S, Aksu TA, Gümüşlü S, Korgun DK, Canatan D (2001) Antioxidant capacity of G-6-PD-deficient erythrocytes. Clin Chim Acta 303: 83–86.CrossRefPubMedGoogle Scholar
  5. Blackburn H (1991) The potential for prevention of atherosclerosis in children. Ann N Y Acad Sci 623: 2–8.CrossRefPubMedGoogle Scholar
  6. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 350: 1495–1504.CrossRefPubMedGoogle Scholar
  7. Cathcart MK (2004) Regulation of superoxide anion production by NADPH oxidase in monocyte/macrophages: contribution to atherosclerosis. Arterioscl Thromb Vasc Biol 24: 23–28.CrossRefPubMedGoogle Scholar
  8. Cavalli Sforza LL, Piazza A (1993) Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Gen 1: 3–18.Google Scholar
  9. Chan TK, Todd W, Wong CC (1965) Tissue enzyme levels in erythrocyte glucose 6-phosphate dehydrogenase deficiency. J Lab Clin Med 66: 937–942.PubMedGoogle Scholar
  10. Cocco P, Manca P, Dessì S (1987) Preliminary results of a geographic correlation study on G6PD deficiency and cancer. Toxicol Pathol 15: 106–108.PubMedCrossRefGoogle Scholar
  11. Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias R (1998) Mortality in a cohort of men expressing the glucose 6-phosphate dehydrogenase deficiency. Blood 91: 706–709.PubMedGoogle Scholar
  12. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A (2001) Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 11: 328–343.PubMedGoogle Scholar
  13. De Vita G, Alcalay M, Sampietro M, Cappellini MD, Fiorelli G, Toniolo D (1989) Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet 44: 233–240.PubMedGoogle Scholar
  14. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279: 1615–1622.CrossRefPubMedGoogle Scholar
  15. Endres M (2006) Statins. Potential new indications in inflammatory conditions. Atherosclerosis Supplements 7: 31–35.CrossRefPubMedGoogle Scholar
  16. Feron O, Dessy C, Moniotte S (1999) Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 103: 897–905.CrossRefPubMedGoogle Scholar
  17. Filosa S, Calabrò V, Lania G, et al (1993) G6PD haplotypes spanning Xq28 from F8C to red/green color vision. Genomics 17: 6–14.CrossRefPubMedGoogle Scholar
  18. Fortuño A, San José G, Moreno MU, Beloqui O, Dìez J, Zalba G (2006) Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 55: 209–215.CrossRefPubMedGoogle Scholar
  19. Gimbrone MA, Kume N, Cibulsky M (1993) Vascular endothelial dysfunction and the pathogenesis of atherosclerosis. In: Weber P, Leaf A, eds. Atherosclerosis Reviews. New York: Raven Press, 25, 1–9.Google Scholar
  20. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425–430.CrossRefPubMedGoogle Scholar
  21. Gorog DA, Rakhit R, Parums D, Laffan M, Davies GJ (1998) Raised factor VIII is associated with coronary thrombotic events. Heart 80: 415–417.PubMedGoogle Scholar
  22. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160–1164.CrossRefPubMedGoogle Scholar
  23. Kirkman HN (1968) Glucose 6-phosphate dehydrogenase variants and the drug-induced hemolysis. Ann N Y Acad Sci 151: 753–764.PubMedGoogle Scholar
  24. Kornberg A, Horeker BL, Smyrniotis PZ (1955) Glucose 6-phosphate dehydrogenase. In: Methods in Enzymology. New York, Academic Press, 323–327.CrossRefGoogle Scholar
  25. Leopold JA, Cap A, Scribner AW, Stanton R, Loscalzo J (2001) Glucose 6-phosphate dehydrogenase deficiency promotes endothelial oxidative stress and decreases endothelial nitric oxide bioavailability. FASEB J 15: 1771–1773.PubMedGoogle Scholar
  26. Long WK, Wilson SW, Frenkel EP (1967) Association between red cell glucose 6-phosphate variants and vascular disease. Am J Hum Genet 19: 35–53.PubMedGoogle Scholar
  27. Luzzatto L, Mehta A, Vulliamy T (2001) Glucose 6-phosphate dehydrogenase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 4517–4553.Google Scholar
  28. Matsui R, Xu S, Maitland KA, et al (2005) Glucose-6 phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation 112: 257–263.CrossRefPubMedGoogle Scholar
  29. Matsui R, Xu S, Maitland KA, et al (2006) Glucose-6 phosphate dehydrogenase deficiency decreases vascular superoxide anion and atherosclerotic lesions in Apoliporotein E−/− mice. Arterioscler Thromb Vasc Biol 26: 910–916.CrossRefPubMedGoogle Scholar
  30. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109–142.PubMedGoogle Scholar
  31. Muntoni S (2003) G-6-PD deficiency: a naturally-occurring model of HMG-CoA reductase restraint. Ann Nutr Metab 47: 229–254 (Abstract, pp. 241–242).CrossRefGoogle Scholar
  32. Muntoni S, Muntoni Sa (2001) Genetic influences on serum LDL levels and type 1 diabetes incidence in Sardinia. In: Simopulos AP, Pavlou KN, eds. Nutrition and Fitness: Diet, Genes, Physical Activity and Health. Basel: Karger, 89, 76–82.CrossRefGoogle Scholar
  33. Muntoni S, Batetta B, Dessì S, Muntoni Sa, Pani P (1992) Serum lipoprotein profile in the Mediterranean variant of glucose 6-phosphate dehydrogenase deficiency. Eur J Epidemiol 8(Supplement 1): 48–53.CrossRefPubMedGoogle Scholar
  34. Nikolaidis MG, Jamurtas AZ, Paschalis V, et al (2006) Exercise-induced oxidative stress in G6PD-deficient individuals. Med Sci Sports Exerc 28: 1443–1450.Google Scholar
  35. Oluboyede OA, Esan GJF, Francis TI, Luzzatto L (1979) Genetically determined deficiency of glucose 6-phosphate dehydrogenase (type A-) is expressed in the liver. J Lab Clin Med 93: 783–789.PubMedGoogle Scholar
  36. Park J, Choe SS, Choi AH, et al (2006) Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes 55: 2939–2949.CrossRefPubMedGoogle Scholar
  37. Sanna E, Bruno R, Cosseddu GG, Floris G, Salis A, Silvetti M (1990) Present-day G-6-PD deficit in Sardinia with respect to malarial morbidity and mortality in the past. Z Morph Anthrop 70: 257–267.Google Scholar
  38. Scandinavian Simvastatin Survival Study (4S) (1997) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.Google Scholar
  39. Schwartz AG, Pashko LL (2004) Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171–187.CrossRefPubMedGoogle Scholar
  40. Sheperd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307.CrossRefGoogle Scholar
  41. Siniscalco M, Bernini L, Latte B, Motulski G (1961) Favism and thalassemia and their relationship to malaria. Nature 190: 1179–1180.CrossRefGoogle Scholar
  42. Siperstein MD (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25: 1462–1468.PubMedGoogle Scholar
  43. Wattanasuwan N, Khan IA, Gowda RM, Vasavada BC, Sacchi TJ (2001) Effect of acute myocardial infarction on cholesterol ratios. Chest 120: 1196–1199.CrossRefPubMedGoogle Scholar
  44. Zalba G, Beloqui O, San José G, Moreno MU, Fortugño A, Diez J (2005) NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 25: 1452–1457.CrossRefPubMedGoogle Scholar
  45. Zeiher AM (1996) Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 348(Supplement I): s10–s12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • L. Meloni
    • 1
  • M. R. Manca
    • 1
  • I. Loddo
    • 1
  • G. Cioglia
    • 1
  • P. Cocco
    • 2
  • A. Schwartz
    • 3
  • S. Muntoni
    • 4
  • Sa. Muntoni
    • 4
    • 5
  1. 1.Department of Cardiovascular and Neurological Sciences, Heart UnitUniversity School of CagliariCagliariItaly
  2. 2.Department of Public Health, Occupational Medicine UnitUniversity School of CagliariCagliariItaly
  3. 3.Fels InstituteTemple University School of MedicinePhiladelphiaUSA
  4. 4.Centre For Metabolic Diseases and AtherosclerosisThe ME.DI.CO. AssociationCagliariItaly
  5. 5.Dipartimento di Tossicologia, Sezione di Oncologia e Patologia MolecolareUniversità degli Studi di CagliariCagliariItaly

Personalised recommendations